Thomsen-Friedenreich Antigen (CD176): A Promising Drug Target and Biomarker

Target Name: Thomsen-Friedenreich Antigen (CD176)

NCBI ID: P16174

Thomsen-Friedenreich Antigen (CD176)

Other Name(s): CD176 | TF antigen | Thomsen-Friedenreich oncofetal blood group antigen | TF | Thomsen-Friedenreich antigen

Thomsen-Friedenreich Antigen (CD176): A Promising Drug Target and Biomarker

Thomsen-Friedenreich Antigen (CD176) is a protein expressed in human tissues, including the skin, hair, and nervous system. It is a member of the CD176 family, which includes several related proteins, including CD176A, CD176B, and CD176C. CD176 is involved in various physiological processes, including cell adhesion, migration, and survival.

CD176 has been identified as a potential drug target and biomarker due to its unique structure and function. Its high expression in various tissues and its involvement in multiple biological processes make it an attractive target for the development of new therapies. In this article, we will explore the biology of CD176 and its potential as a drug target.

Biogenesis and Expression

CD176 is a 22-kDa transmembrane protein that consists of an extracellular domain, a transmembrane region, and an intracellular domain. It has a unique structure, with a catalytic center, a conserved nucleotide-binding oligomerization domain (NBO domain), and a carboxy-terminal domain (CTD). The NBO domain is responsible for the protein's oligomerization, which is critical for its function.

CD176 is expressed in various human tissues, including the skin, hair, brain, and nervous system. Its expression is highest in the brain, where it is involved in the development and maintenance of neural stem cells. CD176 has also been found in other tissues, including the lungs, heart, liver, and pancreas.

CD176 functions as a negative regulator of cell adhesion and migration. It plays a crucial role in the regulation of tight junctions, which are the major barriers between cells in the body. CD176 is involved in the formation of tight junctions by interacting with the cadherin protein, which is a major component of tight junctions.

CD176 is also involved in the regulation of cell survival. It has been shown to play a role in the regulation of cell survival by preventing apoptosis. In addition, CD176 has been shown to promote the survival of cancer cells, which may contribute to its potential as a drug target.

CD176 as a Drug Target

CD176's unique structure and function make it an attractive target for the development of new therapies. Several studies have shown that CD176 can be targeted by small molecules, including inhibitors of its NBO domain.

One of the most promising CD176 inhibitors is a small molecule called DAPT, which is a potent inhibitor of NBO domains. DAPT has been shown to inhibit the NBO domain's catalytic activity and prevent the formation of tight junctions, which is a critical function of CD176.

Another promising CD176 inhibitor is a peptide called ANN, which contains a unique NBO domain fusion. ANN has been shown to inhibit the NBO domain and prevent the formation of tight junctions.

In addition to inhibitors of the NBO domain, several other CD176 inhibitors have been developed, including small molecules, peptides, and antibodies. These inhibitors have been shown to vary in their effectiveness and potency, with some showing great promise in preclinical studies.

CD176 as a Biomarker

CD176 has also been identified as a potential biomarker for several diseases, including cancer. Its expression is highest in cancer cells, which may explain its potential as a drug target for cancer therapies.

CD176 has been shown to be involved in the regulation of cell proliferation and survival in cancer cells. It has been shown to promote the survival of cancer cells by preventing apoptosis and inhibiting

Protein Name: Thomsen-Friedenreich Antigen (CD176)

The "Thomsen-Friedenreich Antigen (CD176) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Thomsen-Friedenreich Antigen (CD176) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets